Jana Frey, MBA
Business Development Manager
Central & Eastern Europe

Cochlear AG
EMEA Headquarters
Peter Merian-Weg 4
CH-4052 Basel (Switzerland)
phone: +41 61 2050 404
mobile: +49 172 2 44 48 99
jfrey@cochlear.com
www.cochlear.com

Clinical background & clinical evidence of the advanced bone conduction solution Baha® 3

For more than 30 years now Cochlear has helped over 250,000 people with moderate to profound hearing loss to connect to the world of sound. Making evidence-based choices and investing heavily in innovation, we support patients to benefit from our solutions for life. As published in global scientific literature Baha is a simple and effective hearing solution for people with conductive and mixed hearing losses and single-sided sensorineural deafness. Baha 3 offers advanced signal processing, improved speech understanding and an implant more stable than ever before. When to choose Baha as a treatment option? When the conductive component is greater than 30 dB, Baha should be the amplification method of choice. Baha bypasses the conductive element delivering amplification more effectively than an air conduction hearing aid. In mixed hearing losses, air conduction hearing devices must compensate for both the conductive and sensorineural element. Unlike sensorineural losses that are amplified according to the half-gain rule, the conductive component requires up to 100% compensation. By completely avoiding the conductive element and delivering sound directly to the cochlea, Baha reduces required gain, resulting in less feedback and distortion. In single-sided deafness (SSD), Baha will bypass the deaf ear entirely and deliver sound directly to the hearing cochlea. This will overcome the head shadow effect, which leads to improved speech understanding and 360-degree sound awareness. Baha can be preoperatively tested and evaluated both in clinical and home conditions.

conductive and mixed hearing losses, single-sided sensorineural deafness (SSD); chronic otitis media (COM); atresia/microtia; Treacher Collins syndrome (TCS)/Franceschetti; Goldenhar syndrome (Oculo-Auriculo-Vertebral-OAV); Down syndrome, acoustic neuroma (Vestibular Schwannoma-VS)